Study design for retrospective database analyses and prospective real-world evidence generation
The systematic methodology for designing observational studies to generate robust evidence from existing electronic health records (claims, registries, EMRs) or by prospectively collecting new data outside of randomized controlled trials, adhering to regulatory and scientific standards.
This skill is highly valued because it enables evidence-based decision-making for market access, regulatory submissions, and clinical development using real-world patient data, which is often more generalizable, timely, and cost-effective than traditional trial data. It directly impacts a company's ability to demonstrate product value, secure reimbursement, and inform clinical practice.
1Careers
1Categories
9.0 Avg Demand
15%
Avg AI Risk
How to Learn Study design for retrospective database analyses and prospective real-world evidence generation
1. Foundational Epidemiology & Statistics: Grasp concepts like confounding, bias (selection, information), causal inference vs. association, and basic study designs (cohort, case-control, cross-sectional). 2. Regulatory & Methodological Frameworks: Study ICH E10, FDA/EMA guidance on Real-World Evidence, and the STROBE checklist for reporting observational studies. 3. Data Source Comprehension: Understand the structure, strengths, and limitations of key data types (claims, EMR, registries).
1. Move to practice by designing a protocol for a simple retrospective cohort study using a claims database (e.g., MarketScan) to answer a drug utilization question. 2. Intermediate Methods: Learn to apply specific techniques like propensity score matching, instrumental variables, or disease risk scores to address confounding. 3. Common Mistakes to Avoid: Avoid immortal time bias, incorrect index date definition, and inappropriate comparator selection.
1. Master the design of complex, multi-database studies with federated analysis or common data model (CDM) harmonization. 2. Strategic Alignment: Design prospective registry studies or pragmatic trials that directly feed into health technology assessment (HTA) dossiers and label expansions. 3. Mentoring & Governance: Lead the development of an organizational evidence generation playbook and mentor junior analysts on protocol design and bias mitigation.
Practice Projects
Beginner
Project
Design a Retrospective Cohort Study Protocol
Scenario
You are a junior analyst at a pharmaceutical company. Your manager asks you to draft a study protocol to compare the incidence of hospitalization for heart failure between patients newly initiated on Drug A vs. Drug B using a US claims database.
How to Execute
1. Define a clear PICO(T) question: Population (new users, inclusion/exclusion), Intervention (Drug A), Comparator (Drug B), Outcome (hospitalization for HF, validated via ICD codes), Time (follow-up period). 2. Specify data source and its key variables. 3. Detail the statistical analysis plan (SAP), including how you will define baseline covariates and adjust for confounding (e.g., multivariable Cox regression). 4. Draft the protocol following a standardized template (e.g., from the DIA or ISPOR).
Intermediate
Case Study/Exercise
Mitigate Critical Biases in an Existing Study Design
Scenario
A senior colleague presents a flawed study design comparing long-term outcomes of two diabetes drugs. The design selects patients only after 6 months of continuous treatment, creating potential immortal time and selection bias.
How to Execute
1. Identify and articulate the specific biases: 'This design introduces immortal time bias because the 6-month treatment persistence requirement is part of the outcome definition. It also creates selection bias by excluding early discontinuers, who may differ systematically.' 2. Propose a corrected design: Use an 'intention-to-treat' or 'as-treated' approach starting from the index date, and justify your choice. 3. Suggest a sensitivity analysis (e.g., varying the grace period) to test the robustness of the results.
Advanced
Project
Architect a Prospective Real-World Evidence Generation Strategy
Scenario
You are the Head of RWE. Your company is launching a new oncology drug and needs a multi-year evidence plan to support global reimbursement and label expansion into a new sub-population, requiring prospective data collection.
How to Execute
1. Map evidence gaps to stakeholder requirements (payers, regulators, clinicians). 2. Design a hybrid approach: a) a large, pragmatic registry study using existing hospital networks (EMR), and b) a targeted prospective cohort study with patient-reported outcomes (PROs) in key markets. 3. Develop a data governance and privacy framework for international data pooling. 4. Create a detailed project plan with milestones, KPIs, and a budget, ensuring alignment with cross-functional teams (Medical Affairs, Market Access, Regulatory).
Tools & Frameworks
Mental Models & Methodologies
PICO(T) FrameworkTarget Trial Emulation (TTE) FrameworkSTROBE ChecklistHill's Criteria for Causality
PICO(T) structures the research question. TTE is the gold standard for designing observational studies to mimic a randomized trial. STROBE ensures rigorous reporting. Hill's Criteria help assess strength of evidence for causal claims from observational data.
These are core methods for confounding control. Selection depends on the data structure and potential biases (e.g., using IVs for unmeasured confounding, ITS for policy changes).
Software & Platforms (Data & Analysis)
Common Data Models (OMOP CDM, Sentinel)Statistical Software (R, SAS, Python with statsmodels)Database Platforms (IQVIA PharMetrics, Optum Clinformatics)Protocol Templates (ISPOR, DIA)
CDMs enable standardized, multi-site analyses. R/SAS are required for sophisticated modeling. Knowledge of major commercial and government claims/EMR databases is essential. Standard templates ensure regulatory-grade protocol design.
Interview Questions
Answer Strategy
The interviewer is testing systematic thinking and knowledge of bias mitigation. Use the Target Trial Emulation framework as your backbone. Answer strategy: 1) Define the target trial (eligibility, treatment strategies, outcomes, follow-up). 2) Translate each component to the observational setting, emphasizing new-user design, active comparator, and validated outcome definitions. 3) Explicitly name and plan for biases: confounding (via high-dimensional propensity scores or disease risk scores), immortal time (using time-conditional models), and selection bias (clear inclusion/exclusion). Sample Answer: 'I would design a retrospective new-user cohort study using an active comparator, emulating a target trial. First, I'd define a new-user cohort by the first prescription date, applying strict inclusion/exclusion criteria. To control for confounding, I would use high-dimensional propensity score matching on a vast set of covariates. To avoid immortal time bias, I would analyze time-to-event from index date, censoring at switch or disenrollment. I'd validate stroke outcomes using a combination of diagnosis codes and hospitalization records.'
Answer Strategy
Testing for vigilance, technical depth, and communication. Use the STAR (Situation, Task, Action, Result) method. The core competency is the ability to critically evaluate methods. Sample Answer: 'In a review of a claims-based study on a rare adverse event, I noticed the comparator group was defined as 'non-users' rather than users of an alternative therapy. I identified this as a critical design flaw, as non-users inherently have a different health status (healthy-user bias). I presented this concern with a diagram illustrating the biased selection process. The team redesigned the study to include an active comparator, which fundamentally changed the results and avoided a potentially misleading conclusion for regulators.'
Careers That Require Study design for retrospective database analyses and prospective real-world evidence generation